J Cancer 2024; 15(1):54-67. doi:10.7150/jca.88261 This issue Cite

Review

Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

Xiaohan Tong, Chunyan Dong, Shujing Liang

Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

Citation:
Tong X, Dong C, Liang S. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. J Cancer 2024; 15(1):54-67. doi:10.7150/jca.88261. https://www.jcancer.org/v15p0054.htm
Other styles

File import instruction

Abstract

Graphic abstract

Mucin1 is a highly glycosylated type 1 transmembrane mucin that ranks second among 75 tumor-related antigens published by the National Cancer Institute, and has been identified as a possible therapeutic target over the past 30 years. MUC1 plays an important role in malignant transformation and disease evolution, including cell proliferation, survival, self-renewal, and metastatic invasion. MUC1 has been shown to interact with diverse effectors such as β-catenin, receptor tyrosine kinases, and cellular-abelsongene, which are of importance in the pathogenesis of various malignant tumors. Targeting MUC1 has been shown to be an effective way to induce tumor cell death in vivo and in vitro models. In recent years, a number of therapeutic strategies targeting MUC1 have been developed and their value for tumor therapy have been demonstrated experimentally. This review summarizes recent findings on the structure of MUC1, its expression in different tumors and its involved mechanism pathways, with emphasis on new progress in cancer therapy which related MUC1 in the past decade and evaluates their therapeutic effect.

Keywords: MUC1, cancer, immunotherapy, targeted therapy, combination therapy


Citation styles

APA
Tong, X., Dong, C., Liang, S. (2024). Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. Journal of Cancer, 15(1), 54-67. https://doi.org/10.7150/jca.88261.

ACS
Tong, X.; Dong, C.; Liang, S. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. J. Cancer 2024, 15 (1), 54-67. DOI: 10.7150/jca.88261.

NLM
Tong X, Dong C, Liang S. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. J Cancer 2024; 15(1):54-67. doi:10.7150/jca.88261. https://www.jcancer.org/v15p0054.htm

CSE
Tong X, Dong C, Liang S. 2024. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. J Cancer. 15(1):54-67.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image